Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.
Maryanoff
Bruce E
BE
Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, Spring House, Pennsylvania 19477-0776, USA. bmaryano@prdus.jnj.com
D000818:Animals; D001363:Awards and Prizes; D056649:Cathepsin G; D002403:Cathepsins / Q000037:antagonists & inhibitors*; D053818:Chymases; D006801:Humans; D008958:Models, Molecular; D012697:Serine Endopeptidases / Q000378:metabolism*; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013917:Thrombin / Q000037:antagonists & inhibitors*; D053802:Tryptases
D015842:Serine Proteinase Inhibitors; D002403:Cathepsins; D012697:Serine Endopeptidases; C534094:CTSG protein, human; D056649:Cathepsin G; D053818:Chymases; D013917:Thrombin; D053802:Tryptases